Buy KPV 5mg

KPV (Lys-Pro-Val) is a C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH), encompassing the terminal three amino acids of this 13-residue peptide. Despite its small size, KPV retains the core anti-inflammatory bioactivity of the full α-MSH molecule by acting as an agonist at melanocortin receptors, particularly MC1R and MC3R, which are expressed on immune cells, epithelial cells, enterocytes, and neurons throughout the body. Melanocortin receptor activation triggers a well-characterised intracellular signalling cascade: Gαs-coupled cAMP elevation, followed by PKA activation, which in turn phosphorylates CREB and activates NF-κB inhibitory mechanisms. The net result is a profound downregulation of pro-inflammatory transcription. The NF-κB suppression mediated by KPV is the mechanistic centrepiece of its anti-inflammatory activity. NF-κB is the master transcription factor for acute inflammatory gene expression; its targets include TNF-α, IL-1β, IL-6, IL-8, iNOS, COX-2, and a suite of adhesion molecules (ICAM-1, VCAM-1) responsible for leukocyte recruitment to inflamed tissue. By blocking IκB kinase (IKK) phosphorylation and stabilising the inhibitory IκBα protein, KPV prevents NF-κB nuclear translocation and effectively turns off the inflammatory gene expression programme. This mechanism is shared with glucocorticoids but achieved without binding to the glucocorticoid receptor, meaning KPV's anti-inflammatory effects come without the HPA axis suppression, immunosuppression, or metabolic side effects associated with steroid use. A particularly important feature of KPV biology is its effectiveness at mucosal surfaces. KPV is resistant to luminal proteolysis to a degree unusual for a tripeptide, and its small size facilitates paracellular and transcellular uptake by intestinal epithelium. Once internalised, it acts directly on enterocytes and subepithelial immune cells to reduce inflammatory cytokine production and improve tight junction integrity — the barrier function of the intestinal epithelium that is compromised in inflammatory bowel disease. Studies in colitis models demonstrate that oral KPV reduces mucosal cytokine levels, decreases crypt dropout, and preserves villous architecture more effectively than topical application alone, suggesting functional uptake from the gut lumen. KPV also demonstrates modulatory effects on mast cell degranulation. By activating MC1R on mast cells, it raises the threshold for IgE-mediated and complement-triggered degranulation, reducing histamine and prostaglandin release without ablating the mast cell response entirely. This makes KPV of particular research interest in allergic and atopic models alongside its better-characterised IBD and systemic inflammation applications. Additionally, KPV crosses the blood-brain barrier and reduces neuroinflammation via MC1R/MC3R expressed on microglia, suggesting potential CNS applications that remain an emerging area of preclinical investigation.

KPV at 5mg vials is appropriate for research focused on inflammatory bowel disease models, mucosal wound healing, systemic anti-inflammatory interventions, and skin inflammatory conditions. The 5mg vial reflects the relatively low dosing requirements for this potent tripeptide; in rodent models, biologically active doses are typically in the range of 100–400 mcg/kg, making 5mg sufficient for multiple experimental animals at standard doses. Researchers investigating oral delivery models should note that nanoparticle encapsulation dramatically improves efficacy for colonic delivery; free peptide orally remains active but at lower overall bioavailability than encapsulated formulations. Quality assessment for KPV requires verification of the exact tripeptide sequence (Lys-Pro-Val, H-Lys-Pro-Val-OH) by mass spectrometry (MW 340.42 g/mol) and HPLC purity ≥98%. Because KPV is a very small peptide, impurity profiles are particularly important — synthesis of tripeptides can leave significant side-product contamination if purification is inadequate. A reputable supplier will provide a CoA showing the specific impurity profile, not merely overall purity. Lyophilised KPV is stable for extended periods at −20°C; reconstituted solution should be used within 3–4 weeks when refrigerated. Researchers can expect anti-inflammatory effects to manifest rapidly relative to structural repair peptides — in acute rodent inflammation models, significant cytokine reduction is evident within 24–72 hours of the first dose. For colitis models, measurable histological improvement typically requires 7–14 days of consistent dosing. KPV is well-suited to combination protocols with structural repair peptides (BPC-157, TB-500) where inflammatory control and tissue reconstruction are both desired, as its mechanism (MC1R/NF-κB) is non-overlapping with the VEGF, PI3K, and actin-based mechanisms of the other agents.

KPV's closest mechanistic comparator is BPC-157 in the anti-inflammatory domain, though their mechanisms are entirely distinct. BPC-157 reduces inflammation primarily through NO pathway modulation and cytoprotective mechanisms, while KPV operates via direct NF-κB suppression through melanocortin receptor agonism. KPV is generally considered the more potent targeted anti-inflammatory of the two — its cytokine-suppressing effects in inflamed tissue are more direct and rapid. However, BPC-157 adds structural repair mechanisms (angiogenesis, fibroblast activation, collagen synthesis) that KPV lacks. In acute injury models where both inflammation and structural damage are present, the combination is superior to either agent alone. Compared to systemic anti-inflammatories used in research contexts — such as dexamethasone or indomethacin — KPV provides a more targeted immunomodulatory profile with significantly fewer off-target effects. It lacks the HPA axis suppression, bone density effects, and metabolic complications of glucocorticoids, and the GI toxicity of NSAIDs. This safety advantage is particularly relevant for long-duration protocols. Against glutathione, KPV is the preferred choice where inflammatory cytokines are the primary target, while glutathione is more appropriate where oxidative stress and mitochondrial protection are the primary concerns. For IBD-specific research, KPV remains one of the most compelling experimental agents available and is increasingly the benchmark comparator against which novel therapeutic candidates are tested.